文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌挽救性放疗期间PSA下降速率预测疾病结局:前瞻性观察研究5年随访

PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome - 5 year follow-up of a prospective observational study.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-05-30

该前瞻性观察研究纳入214例前列腺切除后生化复发接受挽救性放疗的患者,放疗期间每周测PSA并计算PSA下降速率常数k。中位随访4.7年,5年无失败生存率为56%,k是疾病进展的最强预测因子,加入现有临床变量可显著改善结局预测。

要点

  • 挽救性放疗期间每周PSA计算下降速率常数k,是疾病进展最强预测因子。
  • 中位随访4.7年,5年无失败生存率为56%。
  • k加入现有临床变量可显著改善SRT后治疗结局预测。

核心结论

  • PSA下降速率常数k是前列腺癌挽救性放疗后疾病进展的最强预测因子。
  • 将k加入现有临床变量可显著改善对SRT后治疗结局的预测能力。

研究设计与样本

  • 前瞻性观察研究,2013至2016年纳入214例前列腺切除后生化复发接受挽救性放疗的患者。
  • 前列腺床处方剂量70 Gy分35次(7周),不联合激素治疗,放疗期间每周测PSA。
  • 按一级动力学假设为196例合格患者计算PSA下降速率常数k,并用Cox回归、逻辑回归和ROC分析比较其预测能力。

主要发现

  • 中位随访4.7年,估计5年无失败生存率为56%。
  • 单因素和多因素分析中,PSA下降速率常数k均为疾病进展的最强预测因子。
  • 疾病进展定义为SRT后PSA持续上升、PSA较SRT后最低值升高≥0.2 ng/ml、接受激素治疗或临床进展。

关键数值与推荐

  • 前列腺床处方剂量为70 Gy分35次(7周),不联合激素治疗。
  • 疾病进展定义包括SRT后PSA持续上升、PSA较最低值升高≥0.2 ng/ml、激素治疗或临床进展。

临床怎么用

  • SRT期间每周监测PSA并计算下降速率常数k,可辅助预测疾病进展风险。
  • 将k与已知临床预测参数结合,可能帮助个体化制定后续治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Biochemical recurrence after prostatectomy is commonly treated with salvage radiotherapy (SRT). In this prospective observational study we investigated the PSA decay rate, determined by predefined serial PSA measurements during SRT, as a predictor for treatment outcome. MATERIALS AND METHODS: Between 2013 and 2016, 214 patients were included in the study. The prescribed dose to the prostate bed was 70 Gy in 35 fractions (7 weeks) without hormonal treatment. PSA was measured weekly during SRT. Assuming first order kinetics, a PSA decay-rate constant (k) was calculated for 196 eligible patients. The ability of k to predict disease progression was compared with known clinical prediction parameters using Cox regression, logistic regression and ROC analyses. Disease progression was defined as continuously rising PSA after SRT, PSA increase by ≥0.2 ng/ml above nadir after SRT, hormonal treatment or clinical progression. RESULTS: After a median follow up of 4.7 years the estimated failure-free survival at 5 years was 56%. The PSA decay-rate constant (k) was found to be the strongest predictor of disease progression in both uni-and multivariable analyses. CONCLUSION: The addition of k to established clinical variables significantly improves the possibility to predict treatment outcome after SRT and could be used to personalize future therapies.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gunnlaugsson A, Kjellén E, Bratt O, et al. PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome - 5 year follow-up of a prospective observational study. Clin Transl Radiat Oncol. 2020. PMID: 32613088. doi:10.1016/j.ctro.2020.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。